Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 12, 2025 16:05 ET | Source: Alector, Inc.

Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating...
December 01, 2025 16:05 ET | Source: Alector, Inc.

Alector to Participate in the Bank of America CNS Therapeutics Conference

SOUTH SAN FRANCISCO, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating...
November 06, 2025 16:05 ET | Source: Alector, Inc.

Alector Reports Third Quarter 2025 Financial Results and Provides Business Update

Selected lead candidates AL137 for the company’s Alector Brain Carrier (ABC)-enabled anti-amyloid beta antibody in Alzheimer's disease, and AL050 for its ABC-enabled GCase enzyme replacement therapy...
October 21, 2025 16:05 ET | Source: Alector, Inc.

Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating...
September 16, 2025 08:00 ET | Source: Alector, Inc.

Alector to Host Virtual Research and Development Event Highlighting PGRN Franchise and Brain Carrier Programs

SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the...
August 28, 2025 08:00 ET | Source: Alector, Inc.

Alector to Participate in Upcoming Healthcare Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating...
August 07, 2025 16:05 ET | Source: Alector, Inc.

Alector Reports Second Quarter 2025 Financial Results and Provides Business Update

On track to report topline data by mid-Q4 2025 from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN, a severe, rare form of dementia with no approved treatments Ongoing Phase 2...
July 31, 2025 16:05 ET | Source: Alector, Inc.

Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call

SOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating...
June 13, 2025 16:05 ET | Source: Alector, Inc.

Alector Provides Executive Leadership Update

-- Neil Berkley, M.B.A., appointed Interim Chief Financial Officer, succeeding Marc Grasso, M.D., effective June 20, 2025 -- SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) --...
June 03, 2025 08:00 ET | Source: Alector, Inc.

Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating...